On Demand 2018 Friday General Sessions
This collection covers general sessions from Friday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:
- Anaphylaxis In-depth
- Allergy-Immunology Physician Wellness: Challenges, Threats and Opportunities
- Food Allergy Related Mortality
- Has the Therapeutic Use of Oral Immunotherapy for Food Allergy Passed the Tipping Point?
- Integrative Medicine 101: Lotions and Potions? or Possibilities?
- Name that Rash: Serious Drug Rashes and Others
- Phases of Allergy Practice
- Tailoring Treatment Selection to Achieve Optimal Health Outcomes in Patients With HAE
- What to Do When Your Patient is Allergic to Multiple Allergens for Which There are Sublingual FDA Approved Tablets
- What to Do When Your Patients Reach the Yellow Zone
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 13.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical professionals who treat patients with allergic and/or immunological conditions:
- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Nurses and advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals
Upon completion of this session, participants should be able to:
- Describe the personal and professional challenges to physician wellness at all stages of career.
- Discuss the current and future threats to physician wellness for AI physicians
- Describe approaches that can be done personally or professionally (including resources from ACAAI) that can build, maintain or repair physician wellness
- Analyze risk vs benefit of early epinephrine use
- Discuss topics relevant to the early phase of the practice of allergy.
- Discuss topics relevant to the middle phase of the practice of allergy.
- Discuss topics related to the late phase of the practice of allergy and transitioning out of practice.
- Discuss the literature regarding sublingual immunotherapy efficacy and safety.
- Discuss the literature regarding polysensitization and immunotherapy (both SCIT and SLIT).
- Review the differential diagnosis of HAE and differentiate HAE from non-HAE angioedema.
- Describe the limitations of emergency departments in management of acute HAE attacks and the allergist’s role in ensuring patients and other health care providers are prepared for acute attack management.
- Describe current clinical trial evidence regarding the efficacy and safety of approved and emerging therapies for the prevention of HAE attacks.
- Describe what is known of food allergy fatalities in the U.S., and explore questions around food allergy fatalities moving forwards.
- Discuss food allergy-related death in an educated, empowered way, without fear or confusion.
- Identify challenges and potential solutions when approaching the topic of food allergy-related mortality with families.
- Recognize drug-induced rashes associated with high risk of morbidity and mortality.
- Identify specific treatments for certain serious drug rashes.
- Assess the current state-of-the-art in food oral immunotherapy.
- Identify suitable patients for food oral immunotherapy.
- Judge the readiness of the allergist’s practice to begin a food oral immunotherapy program.
- Recognize the frequent practice of integrative (complementary and alternative) medicine.
- Describe the potential risks and benefits associated with integrative medicine.
- Provide a critical review of the literature supporting and opposing the use of integrative medicine to treat atopic disorders.
- Identify risk factors for loss of asthma control in pediatric and adult patients.
- Discuss the concept of dynamic dosing of inhaled corticosteroids for asthma.
- Discuss potential differences in increasing inhaled corticosteroid dosing as yellow zone management in children versus adults.
Sami Bahna, MD, DrPH, FACAAI
Aleena Banerji, MD
Lisa Beck, MD
William E. Berger, MD, MBA, FACAAI
Michael Blaiss, MD, FACAAI
Julie Brown, MD
Stacy Dorris, MD
Mark S. Dykewicz, MD, FACAAI
Stanley Fineman, MD, MBA, FACAAI
Luz S. Fonacier, MD, FACAAI
Marianne Frieri, MD, PhD, FACAAI
Alan Goldsobel, MD, FACAAI
Erika Gonzalez Reyes, MD
Matthew Greenhawt, MD, MSc, MBA, FACAAI
Daniel Jackson, MD
David M. Lang, MD, FACAAI
Mitchell R. Lester, MD, FACAAI
Jay Lieberman, MD, FACAAI
Peter Lio, MD
Gailen Marshall, MD, PhD, FACAAI
Kathleen May, MD, FACAAI
Kevin P. McGrath, MD, FACAAI
Rajan Merchant, MD, FACAAI
Syed Shahzad Mustafa, MD, FACAAI
Harold S. Nelson, MD, FACAAI
Michael Nelson, MD, PhD
Maeve E. O’Connor, MD, FACAAI
Mark O'Hallaren, MD, FACAAI
John J. Oppenheimer, MD, FACAAI
Purvi Parikh, MD
Michael Pistiner, MD, MMSc, FACAAI
Jay M. Portnoy, MD, FACAAI
Melinda Rathkopf, MD, FACAAI
Marissa Shams, MD, FACAAI
Meagan Shepherd, MD, FACAAI
Ellen Sher, MD, FACAAI
Robert Sidbury, MD, MPH
James L. Sublett, MD, FACAAI
Dana V. Wallace, MD, FACAAI
Julie Wang, MD, FACAAI
Susan Waserman, MD, FACAAI
Richard L. Wasserman, MD, PhD, FACAAI
Robert A. Wood, MD
- 13.50 AMA PRA Category 1 Credit™
- 13.50 Attendance
- 1.50 MOC